Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2020-06-12 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2019年度股东大会的法律意见书
AGM Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the legality and validity of the 2019 Annual General Meeting (AGM) of 康芝药业股份有限公司. It details the procedures of convening and holding the AGM, the qualifications of attendees, the agenda items discussed, and the voting results. The document does not contain the actual annual report or financial statements but rather focuses on the legal compliance and validity of the AGM process and resolutions. It is not a full annual report (10-K), nor an audit report, nor a voting results announcement alone, but a legal opinion related to the AGM. Given the content and purpose, the document best fits the category of AGM Information (AGM-R), which includes presentations and materials shared during the AGM, including legal opinions on the meeting's conduct.
2020-06-12 Chinese
关于深圳证券交易所2019年年报问询函的回复公告
Annual Report Classification · 95% confidence The document is a detailed response to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2019 annual report. It discusses various accounting and financial issues such as goodwill impairment tests, litigation contingencies, financial asset details, supplier dependencies, and other financial disclosures related to the 2019 fiscal year. The content is comprehensive, includes financial data, accounting policies, and auditor opinions, and addresses specific questions about the annual report. The document is not a brief announcement or a certification letter but contains substantive financial and management information related to the annual report. Therefore, it should be classified as an Annual Report (10-K). Q1 2020
2020-06-05 Chinese
关于召开2019年度股东大会补充通知的公告（增加临时提案后）
AGM Information Classification · 95% confidence The document is a detailed announcement regarding the convening of the 2019 Annual General Meeting (AGM) of 康芝药业股份有限公司. It includes information about the meeting date, agenda items, voting procedures (both onsite and online), shareholder registration, proxy forms, and other logistical details. The document does not contain the actual annual report, financial statements, or audit reports but rather the notice and supplementary information about the AGM itself. The presence of agenda items such as the 2019 annual report and financial statements to be reviewed at the meeting confirms this is an AGM notice. The document length (6687 characters) and content indicate it is not a brief announcement but a full AGM notification with attachments and instructions. Therefore, the correct classification is AGM Information (AGM-R).
2020-06-01 Chinese
关于全资子公司申请银行贷款并提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement by 康芝药业股份有限公司 regarding its wholly-owned subsidiary's application for a bank loan and the company's provision of guarantees for that loan. It details the loan amount, terms, collateral, board and independent directors' opinions, and related approvals. The document is an announcement of a financing event involving a loan and guarantee, not a financial report, earnings release, or regulatory filing about financial results. It is not a report publication announcement since it contains substantive information about the financing transaction itself. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 3648 characters, which is consistent with an announcement rather than a full report.
2020-06-01 Chinese
关于增加2019年度股东大会临时提案的公告
AGM Information Classification · 95% confidence The document is an announcement from Kangzhi Pharmaceutical Co., Ltd. regarding the addition of a temporary proposal to the 2019 Annual General Meeting (AGM). It discusses procedural details about the proposal submission, shareholder rights, and meeting arrangements. There is no financial data or detailed report content, only an announcement about changes to the AGM agenda. The document length is short (1269 characters) and it serves as a notification rather than a full report. Therefore, it fits the category of AGM Information (AGM-R).
2020-06-01 Chinese
独立董事关于第五届董事会第七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors regarding a specific board meeting (the 7th meeting of the 5th board) of 康芝药业股份有限公司. It discusses approval of a bank loan guarantee for a wholly owned subsidiary. The content focuses on board-level decisions and compliance with regulatory rules related to guarantees and loans. There is no financial data, earnings information, or detailed report content. The document is not an annual or interim report, nor an earnings release. It is not a call transcript or a capital update. It is a formal board/management related announcement about a specific decision. Therefore, the best fitting category is Board/Management Information (MANG). The document length is short and it is a formal opinion from directors, consistent with MANG filings.
2020-06-01 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.